DISCOUNT ZERTIFIKAT - BRISTOL-MYERS SQUIBB | Market Closed - Deutsche Boerse AG 01:10:16 01/06/2024 am IST | ||
| 32.41 EUR | +0.56% |
|
| Current month | -2.88% | ||
| 1 month | -2.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 32.41 | +0.56% |
| 30/24/30 | 32.23 | -0.56% |
| 29/24/29 | 32.41 | +0.65% |
| 28/24/28 | 32.2 | -1.11% |
| 27/24/27 | 32.56 | +0.31% |
Delayed Quote Deutsche Boerse AG
Last update May 01, 2024 at 01:10 am IST
More quotesStatic data
| Product type | Discount-Zertifikate |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PZ0VBF |
| ISIN | DE000PZ0VBF4 |
| Date issued | 31/10/2023 |
| Maturity | 20/12/2024 (202 Days) |
| Parity | 1 : 1 |
| Emission price | 33.12 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 33.96 € |
|---|---|
| Lowest since issue | 31.5 € |
| Spread | 0.05 € |
| Spread % | 0.15% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.09
USD
Average target price
53.19
USD
Spread / Average Target
+29.46%
- Stock Market
- Certificates
- Certificat
